by At the 61st ERA Congress, researchers presented groundbreaking findings on the diagnosis and management of kidney diseases linked to nephrotic syndrome. The study, also published in the New England Journal of Medicine, introduces a novel technique to identify anti-nephrin autoantibodies as a dependable biomarker for disease progression.
Nephrotic syndrome, a condition marked by high protein levels in urine, is associated with various kidney diseases, including minimal change disease (MCD), primary focal segmental glomerulosclerosis (FSGS), and membranous nephropathy (MN). Damage to podocytes, the Kidney Transplant cells responsible for filtering, leads to protein leakage in urine.
Children diagnosed with MCD or FSGS are often labeled with idiopathic nephrotic Syndrome (INS) when the underlying cause remains unknown. This is due to the reluctance to perform invasive kidney biopsies, particularly in children, and the overlapping histological features of these diseases.
Although anti-nephrin autoantibodies have been identified in some patients with MCD and FSGS, their role in disease progression is not fully understood.
The European and American collaborative study introduced an innovative technique, combining immunoprecipitation with enzyme-linked immunosorbent assay (ELISA), to accurately detect anti-nephrin autoantibodies. This new approach opens up possibilities for personalized treatment strategies and improved disease monitoring.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
